OpGen (NASDAQ:OPGN) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGN) in a research note issued to investors on Monday morning. The firm issued a sell rating on the medical research company’s stock.

OpGen Stock Performance

Shares of OPGN stock traded down $0.32 on Monday, reaching $2.26. The stock had a trading volume of 25,601 shares, compared to its average volume of 85,691. OpGen has a 1 year low of $1.65 and a 1 year high of $38.40. The company has a 50 day simple moving average of $2.81 and a 200 day simple moving average of $4.16.

OpGen (NASDAQ:OPGN) last announced its earnings results on Monday, July 8th. The medical research company reported $0.21 earnings per share (EPS) for the quarter. OpGen had a negative return on equity of 1,827.76% and a negative net margin of 997.34%. The business had revenue of $0.17 million for the quarter.

Hedge Funds Weigh In On OpGen

An institutional investor recently bought a new position in OpGen stock. Chase Investment Counsel Corp acquired a new stake in shares of OpGen, Inc. (NASDAQ:OPGN) during the first quarter, according to its most recent disclosure with the SEC. The fund acquired 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned approximately 2.63% of OpGen as of its most recent SEC filing. Hedge funds and other institutional investors own 2.68% of the company’s stock.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.